Cyclerion Therapeutics, Inc. - Special Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the IW-6463 clinical program top line results update conference call. (Operator Instructions)
I would now like to hand the conference to your speaker today, Bill Huyett, Chief Financial Officer. Please go ahead, sir.
Thank you, Jorel. Good morning. Thank you for joining us today. You will have seen our 2 press releases that crossed the wire earlier today. This morning, we'll be discussing the exciting top line findings from Cyclerion's translational pharmacology study, IW-6463, for treating CNS disorders.
From Cyclerion, Peter Hecht, our CEO; Chris Wright, our Chief Medical Officer; and Cheryl Gault, our Strategy and Business development Leader, will cover further remarks. Dr. Andrew Budson, an independent expert in cognitive and behavioral neurology, will also participate in the call.
We'll be reviewing slides that are available from the Investor and Media section of our website during these remarks and encourage you
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |